Taysha Gene Therapies (TSHA)
(Delayed Data from NSDQ)
$2.18 USD
+0.04 (1.87%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $2.18 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Taysha Gene Therapies, Inc. (TSHA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$6.59 | $8.00 | $5.00 | 207.94% |
Price Target
Based on short-term price targets offered by 11 analysts, the average price target for Taysha Gene Therapies, Inc. comes to $6.59. The forecasts range from a low of $5.00 to a high of $8.00. The average price target represents an increase of 207.94% from the last closing price of $2.14.
Analyst Price Targets (11)
Broker Rating
Taysha Gene Therapies, Inc. currently has an average brokerage recommendation (ABR) of 1.08 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 12 brokerage firms. The current ABR compares to an ABR of 1.09 a month ago based on 11 recommendations.
Of the 12 recommendations deriving the current ABR, 11 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 91.67% and 8.33% of all recommendations. A month ago, Strong Buy made up 90.91%, while Buy represented 9.09%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/TSHA.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 11 | 11 | 10 | 10 | 9 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.08 | 1.08 | 1.09 | 1.09 | 1.10 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/27/2024 | BMO Capital Markets | Evan Seigerman | Not Available | Strong Buy |
6/20/2024 | JMP Securities | Silvan C Tuerkcan | Strong Buy | Strong Buy |
6/20/2024 | Cantor Fitzgerald & Co | Kristen Kluska | Strong Buy | Strong Buy |
6/17/2024 | Needham & Company | Gil J Blum | Moderate Buy | Moderate Buy |
6/3/2024 | Robert W. Baird & Co. | Jack K Allen | Strong Buy | Strong Buy |
5/14/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
4/9/2024 | Piper Sandler | Christopher Raymond | Not Available | Strong Buy |
3/21/2024 | Canaccord Genuity | Whitney Ijem | Strong Buy | Strong Buy |
3/1/2024 | Chardan Capital Markets | Yevgeniya Livshits | Strong Buy | Strong Buy |
3/1/2024 | Guggenheim Securities | Debjit Chattopadhyay | Strong Buy | Strong Buy |
3/1/2024 | Truist Securities | Joon Lee | Strong Buy | Strong Buy |
10/24/2023 | Wells Fargo Securities | Yanan Zhu | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.08 |
ABR (Last week) | 1.08 |
# of Recs in ABR | 12 |
Average Target Price | $6.59 |
LT Growth Rate | NA |
Industry | Medical - Generic Drugs |
Industry Rank by ABR | 96 of 252 |
Current Quarter EPS Est: | -0.10 |